Cargando…
COVID-19 Antibody Tests: An Overview
Novel coronavirus (nCoV) first emerged in Hubei province of China in December 2019. The virus initially known as 2019-nCoV was renamed to severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) by the International Committee on Taxonomy of Viruses. The associated disease is known as coronavirus...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Wolters Kluwer - Medknow
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8375937/ https://www.ncbi.nlm.nih.gov/pubmed/34447041 http://dx.doi.org/10.4103/jpbs.JPBS_786_20 |
_version_ | 1783740401495048192 |
---|---|
author | Ravi, Arjun B. Singh, V. P. Prabath Chandran, Roshni Venugopal, Krishnan Haridas, Kaushik Kavitha, R. |
author_facet | Ravi, Arjun B. Singh, V. P. Prabath Chandran, Roshni Venugopal, Krishnan Haridas, Kaushik Kavitha, R. |
author_sort | Ravi, Arjun B. |
collection | PubMed |
description | Novel coronavirus (nCoV) first emerged in Hubei province of China in December 2019. The virus initially known as 2019-nCoV was renamed to severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) by the International Committee on Taxonomy of Viruses. The associated disease is known as coronavirus disease 2019 (COVID-19). As the COVID-19 pandemic has unfolded, interest has grown in antibody testing as a way to measure how far the infection has spread and to identify individuals who may be immune. Molecular diagnostic tests like polymerase chain reaction are developed rapidly, however they are not able to fulfill all the requirements of an epidemic reaction. Hence, to complement molecular diagnostic tests, serology tests emerged as a vital aspect of the overall response by confirming the presence of antibodies during the early stage of the infection. Antibody tests help in assessing herd immunity, data about the ongoing phase of infection, identifying potential donors for convalescent plasma therapy, etc. This review currently focuses on giving an overview about the antibody tests in SARS-CoV-2 infections. |
format | Online Article Text |
id | pubmed-8375937 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Wolters Kluwer - Medknow |
record_format | MEDLINE/PubMed |
spelling | pubmed-83759372021-08-25 COVID-19 Antibody Tests: An Overview Ravi, Arjun B. Singh, V. P. Prabath Chandran, Roshni Venugopal, Krishnan Haridas, Kaushik Kavitha, R. J Pharm Bioallied Sci Review Article Novel coronavirus (nCoV) first emerged in Hubei province of China in December 2019. The virus initially known as 2019-nCoV was renamed to severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) by the International Committee on Taxonomy of Viruses. The associated disease is known as coronavirus disease 2019 (COVID-19). As the COVID-19 pandemic has unfolded, interest has grown in antibody testing as a way to measure how far the infection has spread and to identify individuals who may be immune. Molecular diagnostic tests like polymerase chain reaction are developed rapidly, however they are not able to fulfill all the requirements of an epidemic reaction. Hence, to complement molecular diagnostic tests, serology tests emerged as a vital aspect of the overall response by confirming the presence of antibodies during the early stage of the infection. Antibody tests help in assessing herd immunity, data about the ongoing phase of infection, identifying potential donors for convalescent plasma therapy, etc. This review currently focuses on giving an overview about the antibody tests in SARS-CoV-2 infections. Wolters Kluwer - Medknow 2021-06 2021-06-05 /pmc/articles/PMC8375937/ /pubmed/34447041 http://dx.doi.org/10.4103/jpbs.JPBS_786_20 Text en Copyright: © 2021 Journal of Pharmacy and Bioallied Sciences https://creativecommons.org/licenses/by-nc-sa/4.0/This is an open access journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms. |
spellingShingle | Review Article Ravi, Arjun B. Singh, V. P. Prabath Chandran, Roshni Venugopal, Krishnan Haridas, Kaushik Kavitha, R. COVID-19 Antibody Tests: An Overview |
title | COVID-19 Antibody Tests: An Overview |
title_full | COVID-19 Antibody Tests: An Overview |
title_fullStr | COVID-19 Antibody Tests: An Overview |
title_full_unstemmed | COVID-19 Antibody Tests: An Overview |
title_short | COVID-19 Antibody Tests: An Overview |
title_sort | covid-19 antibody tests: an overview |
topic | Review Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8375937/ https://www.ncbi.nlm.nih.gov/pubmed/34447041 http://dx.doi.org/10.4103/jpbs.JPBS_786_20 |
work_keys_str_mv | AT raviarjunb covid19antibodytestsanoverview AT singhvpprabath covid19antibodytestsanoverview AT chandranroshni covid19antibodytestsanoverview AT venugopalkrishnan covid19antibodytestsanoverview AT haridaskaushik covid19antibodytestsanoverview AT kavithar covid19antibodytestsanoverview |